Investor Presentation

4 Investor presentation First six months of 2022 Novo NordiskⓇ Strategic Aspirations 2025 | Highlights first six months of 2022 Purpose and sustainability (ESG) Commercial execution • Progress towards zero environmental impact: Carbon emissions increased by 49% vs H1 2021 and decreased by 19% vs H1 2019 Adding value to society: Positive EMA opinion on human insulin with more flexible storage options Five months' supply of medication donated to Ukraine Being recognised as a sustainable employer: Share of women in VP+ positions increased to 38% from 35% in H1 2021 Diabetes value market share increased by 1.5%-points to 31.0%2 Obesity care sales increased by 84% at CER to DKK 7.0 billion Rare disease sales were unchanged at CER at DKK 10.6 billion Innovation and therapeutic focus Financials • Light blue indicates developments in Q2 2022 Further raise innovation bar for Diabetes treatment: Successful completion of five phase 3 trials with QW insulin icodec Phase 1 initiated with a QD oral GLP-1/GIP co-agonist Develop superior treatment solutions for obesity Phase 1 initiated with oral amycretin Strengthen and progress Rare disease pipeline Concizumab phase 3 trial successfully completed¹ Phase 2 trial initiated with NDec in sickle cell disease Establish presence in Other serious chronic diseases Phase 2 trial initiated with NNC6019 in cardiomyopathy Sales growth of 16% and Operating profit growth of 14%: • . Sales in International Operations grew by 10% Sales in the US grew by 23% with 71% of sales coming from products launched since 2015 Gross margin positively impacted by continued. productivity gains in Product Supply Free cash flow of DKK 42.7 billion and DKK 27.6 billion returned to shareholders during H1 2022 ¹In people with haemophilia A and B with inhibitors. 2MAT (Moving annual total) value market share. IO: International Operations; QD: Once daily; QW: Once weekly; VP: Vice president; H1: First half The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth.

View entire presentation